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Abstract 
Background: Methadone is an effective therapy for opiate dependence. However, one of the commonest side 
effects is sexual dysfunction among male patients. Buprenorphine is an alternative to methadone. This study aimed 
to compare sexual desire among opiate-dependent male patients on buprenorphine (BMT) and methadone mainte-
nance therapy (MMT).
Methods: This cross-sectional study involved 126 male opiate-dependent patient who were tested for total testos-
terone (TT) and prolactin levels, and were interviewed and completed the Sexual Desire Inventory-2 (SDI-2), Malay 
language of International Index of Erectile Function (Mal-IIEF-15) and the Malay version of the self-rated Montgomery-
Asberg Depression Rating Scale (MADRS-BM) questionnaires.
Results: There were 95 (75.4%) patients on MMT and 31 (24.6%) on BMT. Patients on MMT scored significantly lower 
in the sexual desire domain (Mal-IIEF-15 scores) (p < 0.01), dyadic sexual desire (p = 0.04) and TT plasma level (p < 0.01) 
when compared to BMT group after controlling all the confounders.
Conclusions: Patients on MMT are associated with lower sexual desire when compared with patients on BMT. Smok-
ing may further lower testosterone and, hence, sexual desire in those already on methadone.
Keywords: Sexual desire, Smoking, Methadone, Buprenorphine, Sexual dysfunction
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Sexual desire (SD) is commonly acknowledged as an 
individual’s complex motivational state and an interest 
in sexual objects or activities [1]. It consists of 3 com-
ponents namely sexual drive, sexual motivation, and 
sexual wish [2]. Although sexual desire is considered a 
subjective feeling state which is often influenced by vari-
ous sociocultural contexts, some experts had broadly 
defined this aspect of a person’s sexuality as “a psycho-
logical state subjectively experienced by the individual 
as an awareness that he or she wants or wishes to attain 
a (presumably pleasurable) sexual goal that is currently 
unattainable” [3], or “a psychobiological energy that pre-
cedes and accompanies arousal and tends to produce 
sexual behavior” [2]. In 2015, a consensus statement 
from the Fourth International Consultation on Sexual 
Medicine defined male hypoactive sexual desire disorder, 
based on DSM-5 [4], as“persistently or recurrently defi-
cient (or absent) sexual or erotic thoughts or fantasies 
and desire for sexual activity” [5].
Since methadone maintenance treatment (MMT) is a 
well-recognized effective replacement therapy for opi-
ate dependence [6], for many decades, clinicians have 
been using methadone with significant success in reduc-
ing cases of heroin use [7, 8], criminal activity [9–11], 
unemployment [10, 12], mortality [13–16] and the trans-
mission of infectious diseases [11, 17, 18]. However, one 
of the major side effects caused by methadone among 
male opiate-dependent patients on replacement therapy 
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is sexual dysfunction, such as reduced sexual desire and 
erectile failure, as it is believed that methadone exerts 
stronger inhibition effect on sexual desire than heroin 
[19]. Management for methadone-induced sexual dys-
function remains a challenge for the physicians. Some of 
the ex opioid-dependent patients relapsed after stopping 
or reducing their methadone dose. Furthermore, some 
of them used other illicit drugs to increase their sexual 
desire [20]. Hence, the physicians need other strategies to 
manage sexual dysfunction in this group of patients.
Buprenorphine maintenance therapy (BMT), an 
alternative to MMT, has also been used to treat opioid 
dependence due to its effectiveness in reducing opioid 
use. Unlike methadone, buprenorphine is a partial ago-
nist at the µ and κ opioid receptors, and an antagonist 
at the δ receptors. In a meta-analysis published in 2014 
comparing male patients on methadone and buprenor-
phine, it was shown to have a statistically significant evi-
dence that those males on buprenorphine treatment arm 
had lower sexual dysfunction compared to the ones on 
methadone [21].
Previous studies reported that psychiatric disorder, 
namely depression, is highly prevalent among the MMT 
population with the prevalence rates range from 19 to 
74.3% [22, 23]. Brown et al., [24] and Quaglio et al., [25] 
reported a statistically significant association between 
depression and erectile dysfunction among MMT men. 
However, there were some studies which found no sig-
nificant associations between depression and erectile 
dysfunction [6, 26, 27]. Up to date, there are not many 
studies done to investigate sexual desire among men and 
even fewer studies to explore the relationship between 
sexual desire and depression among MMT or BMT 
patients. Taylor et  al. reported that loss of sexual desire 
was one of the risk factors for relapse and recurrence in 
major depressive patients who initially responded to cog-
nitive therapy in that 2-year cohort study [28]. Besides, 
a prospective, 4-week, non-treatment study was con-
ducted on non-depressed men with and without low 
sexual desire, reported that men with low sexual desire 
disorder were distressed by their low sexual desire more 
frequently when compared to men with normal sexual 
desire [29]. Although previous studies had clearly shown 
that depression and sexual dysfunction were associated, 
the relationship between them remained unclear [24–26, 
30, 31].
Although low sexual desire is not a life-threatening 
condition, the prevalence of sexual dysfunction was 
reported to be in the range of between 21 and 52% [21, 
25]. This has potential impacts on the quality of life 
(QoL) and the intimacy of a relationship [32, 33]. With 
sexual dysfunction presented in a wide spectrum of con-
ditions, ranging from erectile dysfunction, premature 
ejaculation to abnormal orgasms, our main aim of this 
cross-sectional study is to focus on the comparison of 
sexual desire between opioid-dependent men receiving 
methadone and buprenorphine maintenance treatment 
(BMT).
Methods
Sample size
According to a previous study [34], a study with 95 MMT 
and 31 BMT participants would have 80% power to 
detect the low SD level between them with the effect size 
of 0.7 at 95% confidence interval [35].
Study population
This cross-sectional study was conducted in University of 
Malaya Medical Center and University of Malaya Center 
of Addiction Sciences, between September 2016 and Sep-
tember 2017. All the opioid-dependent men who received 
MMT or BMT were approached. Subjects who met all 
inclusion criteria and none of the exclusion criteria were 
recruited into the study. Inclusion criteria included: (a) 
age of more than 18  years with a history of opiate use 
disorder, (b) have sexual partner, and (c) have been on a 
stable dosage of either methadone or buprenorphine for 
more than 8 weeks. Exclusion criteria were: (a) currently 
on treatment for viral disease such as human immunode-
ficiency virus (HIV) or hepatitis, (b) currently on treat-
ment for tuberculosis, (c) concurrent use of androgen 
replacement therapy, phosphodiesterase type 5 inhibitors 
or any home remedies that could increase sexual desire, 
(d) concurrent use of psychotropic medications other 
than methadone or buprenorphine, and (e) any unstable 
medical condition.
Those who met the inclusion criteria and consented 
to participate were asked to fill in a semi-structured 
questionnaire, which included questions on socio-
demographic and clinical factors such as, age, ethnic-
ity, education level, employment status, HIV, hepatitis 
B, hepatitis and other comorbid medical illness. Mean-
while, the Opiate Treatment Index (OTI) was also used 
to evaluate the drug use, risk-taking behavior, social per-
formance, criminality, health status domain of the MMT 
or BMT users. In the drug use domain, a Q score is cal-
culated by adding the amount of the most-two-recent 
drug use and dividing it by the total of the two inter-
vals between used over the past 4 weeks. The higher the 
scores, the poorer the outcome of that particular domain 
[36].
All participants were also interviewed face to face by a 
psychiatrist (First Author) using the Mini International 
Neuropsychiatric Interview (M.I.N.I) [37], which is a 
short structured diagnostic interview based on the Diag-
nostic and Statistical Manual of Mental Disorders, 4th 
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Edition, Text Revision (DSM-IV-TR-IV). In this study, 
M.I.N.I was used to identify any comorbid psychiatric 
disorders, namely mood disorders (major depression, 
bipolar disorder, dysthymia, and suicidality), panic disor-
der, social anxiety disorder, generalized anxiety disorders, 
obsessive–compulsive disorder, post-traumatic stress 
disorder, psychotic disorders, substance dependence and 
abuse, eating disorders, and antisocial personality in the 
patients on MMT or BMT.
Sexual desire (SD) was assessed by the Sexual Desire 
Inventory-2 (SDI-2). This is a 14-item scale measuring 
the sexual desire in cognitive terms [38]. Four items were 
concerned about the frequency of desire which scored on 
an 8-item Likert scale. Ten items were concerned about 
the intensity of the sexual desire which were reported 
on a 9-point Likert scale (0 = no sexual desire, 8 = very 
strong sexual desire). The SDI-2 yields two domain 
scores: dyadic sexual desire (DSD) and solitary sexual 
desire (SSD). DSD refers to individuals’ desire for inti-
macy with other person and SSD refers to individuals’ 
desire in engaging sexual behavior by oneself. All items 
are summed up to dictate the total sexual desire (total 
score = 0 to 109) [38]. This instrument was validated 
in Malay version (SDI-2-BM) in a sample of 70 benign 
prostate hyperplasia (BPH) patients and 70 healthy indi-
viduals with good internal consistency (DSD, Cronbach 
alpha = 0.93 and SSD, Cronbach alpha = 0.88) [39].
Erectile Function (EF) was assessed by Malay language 
of International Index of Erectile Function (Mal-IIEF-15), 
a 15-item self-report measures five domains of the sex-
ual function which included the erectile function, orgas-
mic function, sexual desire, intercourse satisfaction, and 
overall satisfaction over the past1  month [40, 41]. Each 
item is rated on a Likert scale ranging from 0 (or 1) to 
5, and scores are computed according to each domain. 
The higher score is corresponding to a better sexual func-
tion. Mal-IIEF-15 has good internal consistency of each 
domain with the Cronbach alpha of 0.74 and higher [41].
The Malay version of the self-rated Montgomery-
Asberg Depression Rating Scale (MADRS-BM) was used 
to assess the severity of the depressive symptoms among 
MMT and BMT users. This is a self-reported instrument 
consisting of 9 items which were reported on a 3-point 
Likert ranging from 0 (no depressive symptoms) to 3 
(worst depressive symptoms). Higher scores indicate 
greater depression. The MADRS-BM exhibited good 
internal consistency (alpha = 0.78) in the previous study 
[42].
Lastly, all the participants were tested for total testos-
terone (TT) and prolactin. All the bloods samples were 
taken in the morning between 0900 and 1100  h. The 
blood samples were later used to measure the total TT 
and prolactin levels using a competitive immunoassay 
with a direct chemiluminescent technique using ADVIA 
Centaur (Siemens Healthcare) [43].
Statistical Analysis
All analyses were conducted with the Statistical Pack-
age of Social Sciences, version 22.0 (SPSS, Chicago, IL, 
USA). Comparisons of the demographic data and clinical 
characteristics were carried out between the patients on 
methadone and buprenorphine. Normality was checked 
using the Shapiro–Wilk test, prior to the analysis of all 
continuous variables. Independent sample t test was cho-
sen for continuous variable with normal distributions, 
while Mann–Whitney U test was used those which are 
not. As for all categorical variables, the Chi-square and 
Fisher exact tests were used. To compare sexual function 
in patients on MMT and BMT, general linear model (for 
normally distributed variables) and generalized linear 
model (for not normally distributed variables) were used 
while controlling for ethnicity, hepatitis C status, educa-
tion level, Q scores for tobacco and amphetamines, and 
social functioning determined by the OTI. Bonferroni 
multiple testing corrections were used for the pairwise 
comparisons. Univariate linear regression was performed 
for the entire study group with DSD as dependent vari-
ables and MMT vs. BMT, age, BMI, educational level, 
HCV infection, OTI scores, and severity of the depres-
sion (MADRS-BM score) as independent variables. All 
the categorical and nominal variables were entered in the 
regression as dummy variables. p < 0.05 was determined 
as statistical significance using two-sided tests.
Results
In this study, 150 men who had been receiving MMT and 
55 men who had been receiving BMT were approached. 
A total of 126 male patients who fulfilled the inclu-
sion and exclusion criteria consented to take part in 
the study. Four MMT patients and two BMT patients 
refused to participate in the study. The MMT arm con-
sisted of 75.4% (n = 95) of the patients (methadone 
dose = 74.53  mg ± 33.68  mg) while the remaining 24.6% 
(n = 31) made up the BMT group (buprenorphine/nalox-
one dose = 2.44  mg ± 1.81  mg). Demographic and clini-
cal details of the study subjects are shown in Table  1. 
The significant differences between patients in both 
MMT and BMT groups were education level (p < 0.01); 
hepatitis C status (p < 0.01); OTI Q scores for tobacco 
(p < 0.01), social functioning and health (p < 0.01), and 
total MADRS-BM score (p < 0.01) (Table 1).
Comparison of differences was done by using mul-
tivariate analysis of covariance in the SDI-2-BM, Mal-
IIEF-15 scores, total testosterone (TT) and prolactin 
between the MMT and BMT groups. This measure also 
took into account the control of confounders such as 
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Table 1 Demographic and treatment characteristics of all male participants
MMT, methadone maintenance treatment; BMT, buprenorphine maintenance treatment; BMI, body mass index; HBV, hepatitis B; HCV, hepatitis C; OTI, Opioid 
Treatment Index; M.I.N.I., Mini International Neuropsychiatric Interview; MDD, major depressive disorder; GAD, Generalized anxiety disorder; ASD, antisocial disorder; 
MADRS-BM, Malay version of self-rated Montgomery-Asberg Depression Rating Scale; df, degrees of freedom; SD, standard deviation; t, t-test; χ2, Chi square test; Z, 
z-test
* p < 0.05, **p < 0.01
a Based on Mann–Whitney test
MMT (n = 95) BMT (n = 31) df χ2, Z, t p value
Age, years, mean ± SD 43.51 ± 9.82 41.60 ± 9.80 123 0.93 0.37
Daily dose, mean ± SD 74.53 ± 33.68 2.44 ± 1.81 –
Duration of MMT or BMT, mean ± SD 50.07 ± 37.86 64.47 ± 44.21 123 − 1.74 0.08
BMI, mean ± SD 23.64 ± 4.80 23.46 ± 4.23 123 0.19 0.84
Ethnic group, n (%)
 Malay 87 (91.6) 28 (90.3) 3 4.29 0.22
 Chinese 7 (7.4) 1 (3.2)
 Indian 1 (1.1) 1 (3.2)
 Others 0 1 (3.2)
Religion, n (%)
 Islam 87 (91.6) 29 (93.5) 3 1.43 0.69
 Christian 1 (1.3) 1 (3.2)
 Buddha 6 (6.3) 1 (3.2)
 Hindu 2(2.7) 0
 Others 1 (1.1) 0
Education level, n (%)
 No education 1 (1.1) 0 3 16.55 < 0.01**
 Primary 9 (9.5) 12 (38.7)
 Secondary 75 (78.9) 19 (61.3)
 Tertiary 10 (10.5) 0
Employment, n (%) 84 (88.4) 30 (96.8) 1 1.89 0.29
Family history of drug use, n (%) 21 (23.1) 2 (6.5) 1 4.18 0.06
HBV, n (%) 4 (4.2) 0 1 1.35 0.57
HCV, n (%) 43 (45.3) 2 (6.5) 1 15.34 < 0.01**
OTI, mean ± SD
Q scores of drugs  usea
  Tobacco 12.69 ± 9.48 15.75 ± 6.21 123 − 3.23 0.001**
  Alcohol 0.01 ± 0.21 0 123 − 0.79 0.43
  Benzodiazepine 0.02 ± 0.10 0.0007 ± 0.004 123 − 1.14 0.89
  Marijuana 0.0005 ± 0.004 0 123 − 0.85 0.39
  Amphetamines 0.002 ± 0.01 0 123 − 1.41 0.16
  Heroin 0.014 ± 0.104 0 123 − 1.41 0.16
HIV risk-taking 5.16 ± 2.81 5.23 ± 2.61 123 − 0.34 0.73
Criminality 0 0 –
Social  functioninga 5.71 ± 5.34 1.65 ± 2.56 123 − 4.43 0.001**
Healtha 0.46 ± 0.80 0.10 ± 0.31 123 − 2.65 0.008**
M.I.N.I. psychiatric disorder(s), n (%) 15 (15.8) 4 (12.9) 5 8.05 0.153
 Current MDD 1 (0.8) 0 1 0.33 1
 Past history of MDD 2 (1.6) 0 1 0.66 1
 Dysthymia 1 (0.8) 0 1 0.33 1
 Panic disorder 1 (0.8) 0 1 0.33 1
 GAD 0 2 (1.6) 1 6.23 0.06
 ASD 12 (12.6) 2 (11.1) 1 0.90 0.515
Total MADRS-BM score, mean ± SD 3.11 ± 4.00 0.57 ± 1.63 103.07 − 4.22 < 0.01**
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education level, hepatitis C status, total MADRS-BM 
score, Q scores for tobacco, social functioning health 
OTI domains with pairwise comparisons using Bonfer-
roni multiple testing corrections. Our study revealed 
that patients on MMT scored statistically significantly 
lower in the sexual desire domain (Mal-IIEF-15 scores) 
(p < 0.01), DSD (p = 0.04) and TT plasma level (p < 0.01) 
when compared to the BMT group after controlling all 
the confounders (Table 2).
Associated factors and the sexual desire
Only MMT vs BMT groups (β = 0.31, Adj R2 = 0.05, 
p < 0.001) and OTI Q score for tobacco (β = − 0.26, Adj 
R2 = 0.10, p = 0.01) were associated with DSD in linear 
regression by using stepwise method. The MMT vs BMT 
groups were entered as a dummy variable model with 
MMT = 0 and BMT = 1. Age, education level, hepatitis 
C status, OTI Q scores for alcohol, heroin, stimulant, 
cannabis use, social functioning and health domain, and 
severity of the depression showed no significant associa-
tions with DSD.
Discussion
Findings from our study show lower mean score for 
sexual desire (p = 0.001) among male opiate-dependent 
patients treated with MMT compared to those on BMT. 
This indicates that patients on BMT achieved a higher 
sexual desire score after controlling for all possible 
confounders.
In our study, the total testosterone level for male 
patients in the MMT group appeared significantly 
lower (12.46 ± 7.64) when compared to that of the BMT 
group (18.45 ± 9.40) (p = 0.005). This could be explained 
by Smith and Elliot’s study in 2012, where they found 
human and animal data indicating that opioid acted at 
different sites in the hypothalamus–pituitary axis, lead-
ing to an endocrine dysfunction known as opioid asso-
ciated androgen deficiency (OPIAD) [44]. All pituitary 
hormones were decreased, such as luteinizing hormone, 
follicle stimulating hormone, oxytocin, estradiol, and 
obviously the reduction of testosterone hormone resulted 
in hypogonadism. In the same year 2012, Heidari et  al. 
also suggested that lower risk of OPIAD was observed in 
those who were treated with buprenorphine, compared 
to methadone due to the offset of hypothalamic–pitui-
tary axis inhibition related to κ-opiate receptor antago-
nist activity [45], though it was a study conducted on 
animals. Buprenorphine had minimal influence on tes-
tosterone levels [27], as the antagonism of buprenorphine 
κ-opiate receptor might have possibly counteracted 
on the μ-opiate receptor-mediated depression of the 
gonadal axis. In contrast, the pharmacodynamic effects 
of methadone on sexual behavior are similar to those 
anti-androgenic effects [46] presenting with symptoms of 
Table 2 Comparison of  mean Mal-IIEF-15 domain scores, SDI-2-BM, total testosterone and  prolactin in  patients 
with sexual partners in the MMT and BMT groups
BMT, buprenorphine maintenance treatment, MMT, methadone maintenancetreatment; Mal-IIEF-15, Malay version of the International Index of Erectile Function 15; 
SDI-2-BM, Malay version of the Sexual Desire Inventory-2; DSD, dyadic sexual desire; SSD, solitary sexual desire; SD, standard deviation, nmol/L, nanomoles per liter; 
ng/dL, nanograms per decilitre; μIU/mL, macro international units per milliliter
* p < 0.05, ** p < 0.01
a Adjusted mean difference with education Level, hepatitis C status, total Malay version of self-rated Montgomery-Asberg Depression Rating Scale (MADRS-BM) score, 
social functioning total score, health total score and Q score for tobacco as covariates
b Adjusted for multiple comparisons using Bonferroni correction
c A generalized linear model approach was used because the variables were not normally distributed
MMT (n = 95) BMT (n = 31) Mean  differencea p  valueb
mean ± SD mean ± SD
Mal-IIEF-15 domain
 Erectile function 21.09 ± 7.91 23.33 ± 7.71 − 2.23 0.23
 Orgasmic  functionc 7.21 ± 4.97 7.15 ± 2.93 0.06 0.96
 Sexual desire 6.14 ± 1.76 7.59 ± 1.54 − 1.46 0.001**
 Intercourse satisfaction 8.59 ± 3.67 9.60 ± 3.54 − 1.01 0.25
 Overall satisfaction 7.09 ± 2.31 7.93 ± 2.14 − 0.11 0.84
Total 48.87 ± 17.10 59.60 ± 15.97 − 4.75 0.23
DSD 27.74 ± 10.95 33.39 ± 11.18 − 5.66 0.04*
SSD 5.25 ± 5.00 4.15 ± 3.74 1.09 0.37
Total testosterone (nmol/L) 12.46 ± 7.64 18.45 ± 9.40 − 5.99 0.005**
Total testosterone (ng/dL) 359.37 ± 220.35 532.13 ± 271.11
Prolactin (μIU/mL) 162.12 ± 102.69 165.20 ± 67.71 − 2.77 0.91
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testosterone deficiency such as fatigue, weakness, mood 
disturbances, and decrease in libido and sexual function 
[47].
Chronic exposure to tobacco by long-term smoking 
can lead to decrease in serum testosterone level, subse-
quently causing erectile dysfunction in males [48]. In our 
study, those patients in the MMT group scored statisti-
cally significantly lower in the sexual desire domain (Mal-
IIEF-15 scores) (p < 0.01), DSD (p = 0.04) and TT plasma 
level (p < 0.01) when compared to BMT group after con-
trolling all the confounders. This means that if smoking 
habit continues, there is a higher chance of these male 
opiate-dependent patients developing even lower testos-
terone levels, consequently leading to sexual dysfunction. 
Clinicians should, therefore, play an active role in advis-
ing and helping all male patients on methadone therapy 
to cease smoking, to reduce sexual dysfunction among 
them.
In a previous study, it was found that sexual desire does 
not solely depend on its biological component, and its 
psychological component is influenced by the interper-
sonal state (presence or absence of sexual partner) and 
social context [49]. However, in our study, the severity of 
depression and social functioning were not statistically 
significant post-linear regression. This implies that the 
low sexual desire was exclusively caused by methadone in 
this group of patients.
Our study is not without its limitations. First, this is a 
cross-sectional study and recall bias might have taken 
place as we had to rely on self-report data based on 
patient’s memory. Second, in a relatively conservative 
society in Malaysia, participants might have concealed 
their true feelings because they felt uncomfortable to 
reveal everything to the researchers, hence leading to 
the possibility of response bias. Third, all male opioid-
dependent patients were recruited from a university 
hospital methadone clinic and the findings may not be 
generalized to the population with substance misuse. 
Fourth, the clinical severity of opioid dependence, such 
as frequency and duration of opioid use, prior to the 
treatment was not considered in this study. However, it is 
worth noting that our study carries strengths such as the 
inclusion of a sample size determined by power calcula-
tion, exclusion of mental and physical illness associated 
with sexual dysfunction, and the use of validated instru-
ment to measure sexual dysfunction.
Conclusions
The present data suggest that the use of methadone is 
associated with lower sexual desire when compared with 
the use of buprenorphine in opioid-dependent patients, 
but larger studies are needed to confirm the present find-
ings. These results highlight the importance of awareness 
among clinicians who treat sexual desire disorder when 
making treatment decisions in this population. Reducing 
this ubiquitous complication arising from replacement 
therapy will, in the long run, greatly influence the posi-
tive prognosis of their treatment compliance and drug 
dependence.
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